171 related articles for article (PubMed ID: 36971065)
1. Evaluation of the clinical features and laboratory data of patients with severe asthma classified as super-responder or non super-responder to omalizumab treatment: a single-center real-life study.
Cakmak ME; Öztop N; Yeğit OO; Özdedeoğlu Ö
J Asthma; 2023 Oct; 60(10):1862-1868. PubMed ID: 36971065
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the General Characteristics of Patients with Severe Asthma Who Switched from Omalizumab to Mepolizumab versus Patients Who Responded to Omalizumab Treatment: A Real-Life Study.
Cakmak ME; Öztop N; Yeğit OO
Int Arch Allergy Immunol; 2024; 185(2):158-166. PubMed ID: 37992693
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Clinical Features and Laboratory Data of Patients with Severe Eosinophilic Asthma Classified as Super-Responders, Partial Responders, or Nonresponders to Mepolizumab Treatment: A Real-Life Study.
Cakmak ME; Öztop N; Yeğit OO; Özdedeoğlu Ö
Int Arch Allergy Immunol; 2023; 184(8):736-743. PubMed ID: 36996772
[TBL] [Abstract][Full Text] [Related]
4. [A real world study of anti-IgE monoclonal antibody in the treatment of allergic united airway disease].
Sui HJ; Zhen Z; Wang QG; Cong TC; Huang JJ; Hu Y
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Feb; 57(2):273-280. PubMed ID: 36797588
[No Abstract] [Full Text] [Related]
5. Effectiveness of Omalizumab in Severe Allergic Asthma and Nasal Polyposis: A Real-Life Study.
Tiotiu A; Oster JP; Roux PR; Nguyen Thi PL; Peiffer G; Bonniaud P; Dalphin JC; de Blay F
J Investig Allergol Clin Immunol; 2020; 30(1):49-57. PubMed ID: 30931917
[TBL] [Abstract][Full Text] [Related]
6. Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study.
Bidder T; Sahota J; Rennie C; Lund VJ; Robinson DS; Kariyawasam HH
Rhinology; 2018 Mar; 56(1):42-45. PubMed ID: 29288573
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status.
Gevaert P; Mullol J; Saenz R; Ko J; Steinke JW; Millette LA; Meltzer EO
Ann Allergy Asthma Immunol; 2024 Mar; 132(3):355-362.e1. PubMed ID: 37951571
[TBL] [Abstract][Full Text] [Related]
8. The significance of eosinophil and eosinophil lymphocyte ratio (ELR) in predicting response to omalizumab treatment in patients with severe allergic asthma.
Özgen H; Tepetam FM; Bulut İ; Örçen C
Tuberk Toraks; 2021 Mar; 69(1):39-48. PubMed ID: 33853304
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Gevaert P; Omachi TA; Corren J; Mullol J; Han J; Lee SE; Kaufman D; Ligueros-Saylan M; Howard M; Zhu R; Owen R; Wong K; Islam L; Bachert C
J Allergy Clin Immunol; 2020 Sep; 146(3):595-605. PubMed ID: 32524991
[TBL] [Abstract][Full Text] [Related]
10. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma.
Lombardo N; Pelaia C; Ciriolo M; Della Corte M; Piazzetta G; Lobello N; Viola P; Pelaia G
Int J Immunopathol Pharmacol; 2020; 34():2058738420950851. PubMed ID: 32816558
[TBL] [Abstract][Full Text] [Related]
11. Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps.
Tiotiu A; Mendez-Brea P; Ioan I; Romero-Fernandez R; Oster JP; Hoang TC; Roux P; Ochoa-Gutierrez DC; Bonniaud P; de Blay F; Gonzalez-Barcala FJ
Clin Rev Allergy Immunol; 2023 Apr; 64(2):179-192. PubMed ID: 35420388
[TBL] [Abstract][Full Text] [Related]
12. No difference in omalizumab efficacy in patients with asthma by number of asthma-related and allergic comorbidities.
Chen M; Choo E; Yoo B; Raut P; Haselkorn T; Pazwash H; Holweg CTJ; Hudes G
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):666-673. PubMed ID: 33465457
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab Treatment in Uncontrolled Asthma and CRSwNP Patients, with Previous Endoscopic Sinus Surgery, to Improve Quality of Life and Endoscopic Outcomes: a Two-Year Real-Life Study.
Maza-Solano J; Callejon-Leblic A; Martin-Jimenez D; Moreno-Luna R; Gonzalez-Garcia J; Cuvillo A; Sanchez-Gomez S
Curr Allergy Asthma Rep; 2023 Oct; 23(10):555-566. PubMed ID: 37644255
[TBL] [Abstract][Full Text] [Related]
14. [Preliminary clinical observation of omalizumab therapy for moderate to severe asthma].
Wu PH; Dong C; Xie JX; Zhang XX; Liu J; Ouyang M; Ma JJ; Huang WH; Ou CX; Li J; Zhang QL
Zhonghua Jie He He Hu Xi Za Zhi; 2021 Jul; 44(7):611-618. PubMed ID: 34256447
[No Abstract] [Full Text] [Related]
15. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.
Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S
Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Mepolizumab in Patients with Severe Eosinophilic Asthma with/without Nasal Polyposis: A Real-Life Study.
Bravo-Gutiérrez FJ; Miralles-López JC; Valverde-Molina J; Alemany Francés ML; Andújar-Espinosa R; Castilla-Martínez M; Avilés-Inglés MJ; Mora-González A; Pajarón-Fernández MJ; Cabrejos-Perotti S; Meseguer-Arce J; Flores Martín I; Pérez-Fernández V;
Int Arch Allergy Immunol; 2024; 185(3):253-259. PubMed ID: 38035559
[TBL] [Abstract][Full Text] [Related]
17. Discontinuing Omalizumab Treatment in Super-Responder Patients with Allergic Severe Asthma: Can the Baseline Total IgE Level Be Used as a Biological Marker to Decide Discontinuing Omalizumab Treatment?
Arslan B; Paçacı Çetin G; Türk M; Gülmez İ; Yılmaz İ
Int Arch Allergy Immunol; 2022; 183(10):1071-1077. PubMed ID: 35917798
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.
Domingo C; Pomares X; Navarro A; Rudi N; Sogo A; Dávila I; Mirapeix RM
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264494
[TBL] [Abstract][Full Text] [Related]
19. Lung function parameters in omalizumab responder patients: An interesting tool?
Paganin F; Mangiapan G; Proust A; Prudhomme A; Attia J; Marchand-Adam S; Pellet F; Milhe F; Melloni B; Bernady A; Raspaud C; Nocent C; Berger P; Guilleminault L
Allergy; 2017 Dec; 72(12):1953-1961. PubMed ID: 28517027
[TBL] [Abstract][Full Text] [Related]
20. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).
Niven RM; Saralaya D; Chaudhuri R; Masoli M; Clifton I; Mansur AH; Hacking V; McLain-Smith S; Menzies-Gow A
BMJ Open; 2016 Aug; 6(8):e011857. PubMed ID: 27507234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]